Skip to main content
TECH logo

Bio-Techne Corporation (TECH) Stock: Price, Forecast & Analyst Target

Bio-Techne Corporation (TECH) — MoonshotScore 92/100 (Exceptional band), calculated Nov 18, 2026. Price $72.70 (-0.07%), as of the Nov 19, 2026 trading session; market cap $11.4B. Expected results Feb 3, 2027.

Educational signal · not a buy or sell recommendation · How to read this

Market value / cash and short-term investments: 32.47× (cash as of Sep 30, 2026) · expected results Feb 3, 2027

$72.70 −$0.05 (-0.07%) Market Cap $11.4B

Bio-Techne Corporation · TECH · NASDAQ · Healthcare · Biotechnology

Research dated 2026-09-13: Bio-Techne supplies the reagents, instruments and analytical workflows used by research, diagnostic and bioprocessing laboratories; it is a life-science tools vendor, not a drug developer. Consumables generate most sales, so laboratory activity and repeat reagent demand matter more than the biotechnology label suggests. The case depends on whether renewed quarterly growth can become durable while current profitability and cash conversion hold against a demanding valuation.

Price as of Nov 19, 2026

Key Statistics

92 of 100

MoonshotScore v2 · Bio-Techne (TECH)

Exceptional
Business Quality Elite (86)
Financial Safety Fortress (91)
Valuation Full (40)
Growth Durability Compounding (92)
Momentum Surging (91)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

High quality, a fortress balance sheet and elite growth, but a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Fortress; Valuation: Full; Growth Durability: Compounding; Momentum: Surging.

  • quarterly revenue $287M (Q1 FY2026, quarter ended Sep 2025)
  • EPS beat 4 of the last 8 reports
  • Altman Z 16.12 · Piotroski F 6

Helping: business quality, balance-sheet strength, durable growth, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for TECH (57 recorded, newest six shown)
RecordedScoreBand
90Exceptional
90Exceptional
90Exceptional
90Exceptional
92Exceptional
92Exceptional

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$72.70
Change on the day-0.07%
52-week range$43.20–$72.88
Market capitalisation$11.4B—
Price / earnings (trailing)66.03
Shares traded on the day3.31M
Beta (volatility vs the S&P 500)1.27
Dividends per share (last 12 months)$0.40
Dividend yield (last 12 months)0.55%

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $43, high $73, latest $73. 4 reported quarters marked, 2 above and 1 below the recorded estimate. $73 $43 high $73 Feb 4, 2026 · Earnings results · reported above the recorded estimate · close $671May 6, 2026 · Earnings results · reported below the recorded estimate · close $482Aug 12, 2026 · Earnings results · reported above the recorded estimate · close $723Nov 6, 2026 · Earnings results · reported in line with the recorded estimate · close $734 Oct 17, 2025 Nov 19, 2026 · $73 $62Oct 17, 2025$63Oct 31, 2025$59Nov 14, 2025$65Nov 28, 2025$59Dec 12, 2025$59Dec 26, 2025$66Jan 9, 2026$68Jan 23, 2026$67Feb 6, 2026$58Feb 20, 2026$54Mar 6, 2026$51Mar 20, 2026$53Apr 2, 2026$59Apr 17, 2026$55May 1, 2026$43May 15, 2026$52May 29, 2026$54Jun 12, 2026$71Jun 26, 2026$71Jul 10, 2026$72Jul 24, 2026$72Aug 7, 2026$72Aug 21, 2026$72Sep 4, 2026$72Sep 18, 2026$72Oct 2, 2026$73Oct 16, 2026$73Oct 30, 2026$73Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · above the recorded estimate
  • · Earnings results · below the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · in line with the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

Dated events ahead, in order, not to scaleNov 23, 2026, Dividend payment date; Feb 3, 2027, Next results due. Spacing is order only and carries no duration.Nov 19, 20261Nov 23, 20262Feb 3, 2027
  1. Dividend payment dateCompany record
  2. Next results dueProvider estimate
How to read these dates

Events are in date order; the spacing is not a duration scale. Estimated dates can change.

What to watch next

Other perspectives

Council score for Bio-Techne (TECH): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Strong
Financial Safety Strong
Valuation Neutral
Growth Durability Strong
Momentum Strong

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Neutral read
Moon AI lens (model) Neutral read

Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Overvalued
Profit Margin Moderate
Revenue Growth Negative
Debt/Equity Moderate
ROE Neutral
Gross Margin Strong

Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 17, 2026, the Munger lens read the price at that time as overvalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Bio-Techne (TECH), and what does it report?

Short answer · as of

Protein Sciences sells cytokines, growth factors, antibodies, cell-selection products and protein-analysis systems.

Diagnostics and Spatial Biology supplies controls, calibrators, assays and tissue-analysis products for research and clinical workflows.

Reported revenue combines consumables, instruments and royalties, with consumables overwhelmingly dominant. The numbers therefore measure demand across laboratory workflows rather than the commercial progress of a proprietary therapy.

2 · Latest results

What do the latest results show for Bio-Techne (TECH)?

Short answer · as of

The most recent reported quarter, Q1 FY2026, carried revenue of $287M.

Latest-quarter revenue rose sequentially and from the comparable period, while gross profit, operating income and net income remained well above the loss-making comparison. Annual sales were essentially flat, however, even as annual net income rebounded sharply from its depressed base.

Consumable-heavy sales make laboratory usage and reagent replenishment the underlying volume mechanism. The latest release exceeded the revenue expectation and broadly matched the earnings expectation, but recent earnings history has alternated between beats and misses rather than establishing a clean pattern.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Latest quarter · revenue
$299.71M Sep 30, 2026
Latest quarter · R&D
$26.34M Sep 30, 2026
Latest quarter · SG&A
$133.68M Sep 30, 2026
Latest quarter · FMP standardized operating result
$36.60M Sep 30, 2026
Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026$299.71M$26.34M$133.68M$36.60M
Jun 30, 2026$321.19M$23.95M$113.17M$74.28M
Mar 31, 2026$311.42M$23.45M$109.34M$75.50M
Dec 31, 2025$295.88M$23.13M$113.69M$54.46M
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$299.71M Nov 6, 2026
Latest report · revenue estimate
$292.60M Nov 6, 2026
Latest report · revenue vs estimate
Above estimate Nov 6, 2026
Latest report · EPS vs estimate
In line Nov 6, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Nov 6, 2026$299.71M$292.60M$0.4400$0.4400
Aug 12, 2026$321.19M$314.63M$0.5200$0.5190
May 6, 2026$311.42M$316.11M$0.5300$0.5500
Feb 4, 2026$295.88M$290.47M$0.4600$0.4300
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q1 FY2026$287M$38M$0.24 (diluted)
Q2 FY2026$296M$38M$0.24 (diluted)
Q3 FY2026$311M$51M$0.32 (diluted)
Q4 FY2026$321M$55M$0.36 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Bio-Techne (TECH)?

Short answer

Cash and short-term investments were $351.13M at the Sep 30, 2026 balance-sheet date. Operating cash flow was $73.11M for the quarter ended Sep 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.

Operating cash flow stayed positive across the reported quarterly series and strengthened through the latest periods, while capital expenditure remained modest beside cash generation. Cash and short-term investments also rebuilt steadily from the recent low.

Cash plus reported investments exceeds total debt, although cash and short-term investments alone sits slightly below debt and the long-term investments are not classified. Liquidity and distress screens are strong, but valuation multiples remain elevated and cash-flow yield remains modest, leaving little room for a renewed earnings setback.

How much cash does the business generate or use?

Quarterly operating cash flow shows cash generated or used by operations.

Latest quarter · operating cash flow
$73.11M Sep 30, 2026
Previous quarter · operating cash flow
$95.42M Jun 30, 2026
Period endOperating cash flowCapital expenditure (reported)
Sep 30, 2026$73.11M−$5.92M
Jun 30, 2026$95.42M−$8.48M
Mar 31, 2026$86.66M−$9.09M
Dec 31, 2025$82.41M−$5.92M
How to read these figures

Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.

4 · What to check next?

What should you watch next at Bio-Techne (TECH)?

Short answer · as of

The next earnings report is expected on Feb 3, 2027.

Watch whether consumable demand preserves the recent sequential revenue progression, whether gross profit converts into operating income, and whether operating cash flow continues to rebuild cash. Instrument sales matter less to current scale, but placements can support future use of associated assays and reagents.

The upcoming earnings expectation implies revenue below the latest reported level, while longer-range estimates assume renewed expansion. Recent analyst actions moved broadly toward neutral stances, making execution against that growth path more informative than the labels themselves.

What the records here don't tell us

  • The newest quarter held here (Q1 FY2026) was filed Nov 5, 2025 — 12 months ago.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Bio-Techne compare with its peers?

Short answer

Bio-Techne's score ranks 7th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Bio-Techne differs from therapy-focused biotechnology companies because customers buy research inputs, diagnostic controls, analytical instruments and workflow services rather than exposure to a clinical pipeline. Its economics are anchored in consumables, with instruments and royalties providing smaller revenue streams.

That mix can create repeat purchasing around established laboratory workflows, while still tying demand to research activity, diagnostic testing and bioprocessing workloads. The combination of high gross margin, strong liquidity and a rich sales multiple makes durability of consumable demand especially important.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Exelixis, Inc. (EXEL) Named competitor$65.83 Nov 19, 2026$16.1B98 5-pillar Nov 18, 2026
Kiniksa Pharmaceuticals, Ltd. (KNSA) Same industry, near in market value$95.05 Nov 18, 2026$7.47B98 5-pillar Nov 18, 2026
Krystal Biotech, Inc. (KRYS) Same industry, near in market value$315.34 Nov 18, 2026$9.34B96 5-pillar Nov 18, 2026
Ascendis Pharma A/S (ASND) Same industry, near in market value$270.33 Nov 18, 2026$17.7B96 5-pillar Nov 18, 2026
Halozyme Therapeutics, Inc. (HALO) Same industry, near in market value$93.04 Nov 19, 2026$10.6B95 5-pillar Nov 18, 2026
Neurocrine Biosciences, Inc. (NBIX) Same industry, near in market value$162.86 Nov 18, 2026$16.5B95 5-pillar Nov 18, 2026
Bio-Techne (TECH) — this page$72.70$11.4B92
Corcept Therapeutics Incorporated (CORT) Same industry, near in market value$67.79 Nov 18, 2026$7.42B91 5-pillar Nov 18, 2026
TG Therapeutics, Inc. (TGTX) Same industry, near in market value$66.12 Nov 18, 2026$9.99B90 5-pillar Nov 18, 2026
Protagonist Therapeutics, Inc. (PTGX) Same industry, near in market value$127.16 Nov 18, 2026$8.30B88 5-pillar Nov 18, 2026
Alnylam Pharmaceuticals, Inc. (ALNY) Same industry, near in market value$149.40 Nov 18, 2026$20.0B72 5-pillar Nov 18, 2026
Oruka Therapeutics, Inc. (ORKA) Same industry, near in market value$95.74 Nov 18, 2026$6.49B67 5-pillar Nov 18, 2026
Jazz Pharmaceuticals plc (JAZZ) Named competitor$247.77 Nov 18, 2026$15.9B40 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$65.00 – $73.00
Consensus target
$71.67
Median target
$73.00

Consensus record · Captured .

Measured against a quoted price of $72.70 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Nov 1, 2026

Transactions
60
Identified insiders
13
Purchases
0
Sales
0
Other transactions
60

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Institutional ownership
99.7% Period end Sep 30, 2026
Reporting holders
599 Period end Sep 30, 2026
Previous quarter · holders
617 Prior to period end Sep 30, 2026
Holders in provider snapshotShares
Blackrock, INC.14,250,400
Vanguard Capital Management LLC10,250,628
Hbk Investments L P7,732,128
Vanguard Portfolio Management LLC6,348,862
Fil Ltd6,272,729

Tracked investors

Which of the 16 named investors we follow held TECH in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
Bridgewater AssociatesFounded by Ray DalioQ3 20260%$0Sold out (was $1.89M)

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Bio-Techne (TECH)?

Read these with our analysis →

Common Questions About TECH (Healthcare)

The last 2 questions are answered from this page's own dated data, not from the research.

Why is Bio-Techne better understood as a laboratory supplier than a drug developer?

Bio-Techne sells reagents, assays, controls and analytical instruments used by researchers, diagnostic laboratories and bioprocessing customers. Its revenue reflects customer workflow activity rather than approval or sales of a proprietary medicine.

How do Protein Sciences and Diagnostics and Spatial Biology differ at Bio-Techne?

Protein Sciences centers on biological reagents, cell-selection products and protein-analysis workflows. Diagnostics and Spatial Biology focuses on controls, calibrators, diagnostic assays and tissue-based analysis products for research and clinical applications.

Why do Bio-Techne instruments matter when consumables dominate sales?

Instruments embed Bio-Techne within protein and tissue-analysis workflows, while assays and reagents account for most reported sales. Instrument adoption can therefore matter through the consumables used around those workflows, even though instrument revenue is much smaller.

Can Bio-Techne fund reagent development and its dividend from operating cash?

Operating cash flow remained positive throughout the reported quarterly series and recently strengthened, while capital spending stayed comparatively modest. Research expense and dividends remain continuing uses of that internally generated cash, but current liquidity provides substantial flexibility.

What is the TECH stock price today?

The last price recorded for Bio-Techne Corporation (TECH), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the TECH price target?

The analyst consensus price target for Bio-Techne Corporation (TECH), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 82 figures on this page — 1 from SEC filings and earnings calls, 72 from Financial Modeling Prep (FMP), 3 with no recorded source, 5 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • Summary at the top of the page: Business description; Sector / industry (provider taxonomy); Revenue by segment; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Trailing twelve-month ratio set
  • 1. What is Bio-Techne (TECH), and what does it report?: Business description; Revenue by segment; Most recent periodic reports; Annual revenue and net result (USD millions)
  • 2. What do the latest results show for Bio-Techne (TECH)?: Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Revenue by segment; Reported versus estimated, last 8 quarters; Operating cash flow by quarter (USD millions); Recent SEC filings
  • 3. What are the financial strengths and risks for Bio-Techne (TECH)?: Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash against market value; Trailing twelve-month ratio set; Distress and quality screens
  • 4. What should you watch next at Bio-Techne (TECH)?: Revenue by segment; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions); Next earnings report; Analyst revenue and earnings estimates (average); Analyst actions, most recent per firm
  • 5. How does Bio-Techne compare with its peers?: Sector / industry (provider taxonomy); Business description; Revenue by segment; Trailing twelve-month ratio set; Distress and quality screens
  • FAQ: Why is Bio-Techne better understood as a laboratory supplier than a drug developer?: Business description; Sector / industry (provider taxonomy); Revenue by segment
  • FAQ: How do Protein Sciences and Diagnostics and Spatial Biology differ at Bio-Techne?: Business description; Named officers
  • FAQ: Why do Bio-Techne instruments matter when consumables dominate sales?: Business description; Revenue by segment
  • FAQ: Can Bio-Techne fund reagent development and its dividend from operating cash?: Operating cash flow by quarter (USD millions); Annual revenue and net result (USD millions); Cash, investments and debt; Cash and short-term investments over time (USD millions); Recent dividends paid; Dividends per share, last 12 months
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.